Dose Response
@doseresponse.bsky.social
📤 23
📥 137
📝 5
reposted by
Dose Response
Bryan Roth
10 days ago
Mechanistic insights into the therapeutic properties of delta opioid receptor | Science Advances
www.science.org/doi/10.1126/...
loading . . .
Mechanistic insights into the therapeutic properties of delta opioid receptor
Integrated structural and dynamic analyses uncover strategies to target the δ-opioid receptor for improved analgesic efficacy.
https://www.science.org/doi/10.1126/sciadv.aeb6737
0
5
5
reposted by
Dose Response
Bita Moghaddam
19 days ago
New Paper: Psychedelic Therapy vs Antidepressants for the Treatment of Depression Under Equal Unblinding Conditions Main point: psychedelic-therapy is not more effective than open-label SSRIs/SNRIs Study also highlights the influence of blinding integrity
jamanetwork.com/journals/jam...
loading . . .
Psychedelic Therapy vs Antidepressants for the Treatment of Depression Under Equal Unblinding Conditions
This meta-analysis examines the effectiveness of psychedelic-assisted therapy compared with open label–administered traditional antidepressants.
https://jamanetwork.com/journals/jamapsychiatry/article-abstract/2846479
0
8
3
reposted by
Dose Response
Biological Psychiatry
27 days ago
This review proposes using PET imaging to study how menstrual cycle-related ovarian hormone fluctuations and associated neurotransmitter changes drive psychiatric symptoms, particularly in conditions like PMDD and ADHD, to advance precision medicine.
loading . . .
Timing Matters: Leveraging Positron Emission Tomography Imaging and Hormonal Cycles for Precision Psychiatry in Female Mental Health
Fluctuations in behavior across the menstrual cycle have been observed in several psychiatric disorders, particularly those affecting mood. Cycle-specific conditions, such as Premenstrual dysphoric…
https://www.biologicalpsychiatryjournal.com/article/S0006-3223(26)00065-X/fulltext
0
3
1
New PET study links baseline AMPA receptor distribution and post-ketamine regional changes to antidepressant response.
www.nature.com/articles/s41...
loading . . .
The dynamics of AMPA receptors underlies the efficacy of ketamine in treatment resistant patients with depression - Molecular Psychiatry
Molecular Psychiatry - The dynamics of AMPA receptors underlies the efficacy of ketamine in treatment resistant patients with depression
https://www.nature.com/articles/s41380-026-03510-w
about 1 month ago
0
0
0
reposted by
Dose Response
Neuropsychopharmacology
about 1 month ago
This study examined mGluR5 availability in individuals with & without chronic pain across psychiatric diagnoses; ⬇️ availability was associated with ⬆️ depression, anxiety, & executive dysfunction, highlighting mGluR5 as a potential treatment target
loading . . .
In vivo evidence for metabotropic glutamate receptor 5 dysregulation in chronic pain
Neuropsychopharmacology - In vivo evidence for metabotropic glutamate receptor 5 dysregulation in chronic pain
https://www.nature.com/articles/s41386-025-02296-9
0
2
2
reposted by
Dose Response
Phil Corlett
about 1 month ago
Phase 3 effect of COMPASS (3.6 point decrease) half the size of the prior effect? And they changed the definition of response from 50% decrease (which is industry standard) to 25%? The effects are significant. Are they clinically meaningful? (6-9 point drop)
psychedelicalpha.com/news/compass...
0
6
4
lets talk about sex
add a skeleton here at some point
about 2 months ago
0
2
1
Small early-phase, randomized placebo-controlled IV DMT study reports rapid reductions in depression scores vs placebo. Interesting signal, but interpret with the usual psychedelic-trial caveats (functional unblinding, small N, wide CIs)
www.nature.com/articles/s41...
loading . . .
A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial - Nature Medicine
A single intravenous dose of the psychedelic dimethyltryptamine, combined with psychological support, produces rapid and lasting reductions in depressive symptoms in adults with major depressive disor...
https://www.nature.com/articles/s41591-025-04154-z
about 2 months ago
0
0
0
reposted by
Dose Response
Ben Bréant
about 2 months ago
Our paper with
@vyazovskiy.bsky.social
showcasing research conducted at
@ox.ac.uk
@oxforddpag.bsky.social
is out! We describe the effects of the psychedelic 5-MeO-DMT on brain states and sleep via EEG, LFP & freely moving oculometry. Read more:
www.nature.com/articles/s42...
#EEG
#neuroskyence
loading . . .
Vigilance state dissociation induced by 5-MeO-DMT in mice - Communications Biology
Administration of 5-MeO-DMT produces a dissociated brain state in mice, characterized by global slow-wave activity alongside behavioral wakefulness and marked pupil dilation.
https://www.nature.com/articles/s42003-025-09412-x#citeas
0
20
6
reposted by
Dose Response
Eduardo Schenberg, PhD
2 months ago
Has the 🇺🇲 just lost the "non-psychedelic psychedelic" science throne to 🇨🇳 ? 🧪🧠📈 Is there any future left for medical tripping? Hard Qs to ponder over the year...
www.nature.com/articles/s41...
loading . . .
Psychedelics elicit their effects by 5-HT2A receptor-mediated Gi signalling - Nature
Psychedelics and their non-hallucinogenic analogues were compared, revealing that serotonin 2A receptor (5-HT2AR)-mediated Gi signalling is essential for hallucinogenic effect, with the functional mec...
https://www.nature.com/articles/s41586-025-10061-7
0
14
8
reposted by
Dose Response
Alex Kwan
3 months ago
Been waiting for such a study to relate
#psilocybin
dose to 5-HT2AR occupancy in the mouse brain. They found RO₅₀ = 0.88 mg/kg.
journals.sagepub.com/doi/10.1177/...
0
7
2
reposted by
Dose Response
Kate Nautiyal
4 months ago
New paper drop! 🧠💊 Our new paper out in Molecular Psychiatry shows that the serotonin 1B receptor is important for the neural and antidepressant/anxiolytic behavioral responses to psilocybin in mice.
www.nature.com/articles/s41...
loading . . .
The serotonin 1B receptor is required for some of the behavioral effects of psilocybin in mice - Molecular Psychiatry
Molecular Psychiatry - The serotonin 1B receptor is required for some of the behavioral effects of psilocybin in mice
https://www.nature.com/articles/s41380-025-03387-1
6
53
19
reposted by
Dose Response
josh hardman
4 months ago
🐁 Very concerning finding: Psilocybin promotes brain tumour growth Authors caution against use of 5-HT2A agonists like psilocybin in patients with glioma, "given the profound and sustained tumor growth-promoting effects observed." Extends to other serotonergic drugs like LSD.
2
7
5
reposted by
Dose Response
Valentin Riedl
4 months ago
fMRI signals “up,” but neural metabolism might be going “down.” In our
@natneuro.nature.com
paper, we demonstrate that about 40% of voxels with robust BOLD responses exhibit opposite oxygen metabolism, revealing two distinct hemodynamic modes.
rdcu.be/eUPO8
funds
@erc.europa.eu
#neuroskyence
🧵:
4
176
88
reposted by
Dose Response
Alex Kwan
4 months ago
“Basic neuroscience hasn’t produced new drugs.” 💊 Not true - zuranolone (PPD), suzetrigine (pain), gepants (migraine), and more... were born out of a long arc of studies in the lab. I wrote a Perspective on why this matters.
@thetransmitter.bsky.social
www.thetransmitter.org/drug-develop...
loading . . .
How basic neuroscience has paved the path to new drugs
A growing list of medications—such as zuranolone for postpartum depression, suzetrigine for pain, and the gepants class of migraine medicines—exist because of insights from basic research.
https://www.thetransmitter.org/drug-development/how-basic-neuroscience-has-paved-the-path-to-new-drugs/
5
108
48
reposted by
Dose Response
Jay Van Bavel, PhD
4 months ago
A new PNAS paper finds that polarization increased immediately after the invention of smartphones and the advent of social media, which both appeared around the same year, 2008.
www.pnas.org/doi/10.1073/...
18
130
78
reposted by
Dose Response
Elsa Fouragnan
4 months ago
New study out today in Nature Comms:
www.nature.com/articles/s41...
, in which we set out to test whether ultrasound could influence the reward-related learning computations of the nucleus accumbens, building on decades of work on dopaminergic prediction error and reinforcement learning. And it did.
loading . . .
Non-invasive ultrasonic neuromodulation of the human nucleus accumbens impacts reward sensitivity - Nature Communications
This study shows that non-invasive ultrasound to the human nucleus accumbens can modulate deep brain activity and enhance reward-guided learning, offering a potential alternative to invasive neuromodu...
https://www.nature.com/articles/s41467-025-65080-9
6
72
27
reposted by
Dose Response
Alaina Jaster, PhD
5 months ago
My dissertation paper finally dropped in Nature Communications! Overall, the conclusion is that psilocybin may be useful in reducing drug craving that often precipitates relapse through mechanisms related to 5-HT2A activation.
www.nature.com/articles/s41...
loading . . .
Sex-specific role of the 5-HT2A receptor in psilocybin-induced extinction of opioid reward - Nature Communications
Here Jaster et al., show a single psilocybin dose produce sex-specific post-acute changes in opioid reward and withdrawal via 5-HT2A receptors in frontal cortex-to–nucleus accumbens circuits, with epi...
https://www.nature.com/articles/s41467-025-64887-w
2
31
7
reposted by
Dose Response
Jonah Padawer-Curry, PhD
6 months ago
🚨 New science alert! Our cross-species study, now in Nature Neuroscience, demonstrates psychedelics distort how we should interpret functional brain imaging. 👇🧵
nature.com/articles/s41...
#Neuroscience
#Psychedelics
#BrainImaging
loading . . .
Psychedelic 5-HT2A receptor agonism alters neurovascular coupling and differentially affects neuronal and hemodynamic measures of brain function
Nature Neuroscience - Padawer-Curry et al. show that the hallucinogenic 5-HT2A receptor agonist DOI alters neurovascular coupling in mice, with implications for the interpretation of human fMRI...
https://nature.com/articles/s41593-025-02069-z.epdf?sharing_token=EKC7s4NLKHXzwF
1
47
27
reposted by
Dose Response
Matt Wall
6 months ago
New paper in Nature Neuro, with very impressive results (in mice): Single-dose psilocybin rapidly and sustainably relieves allodynia and anxiodepressive-like behaviors in mouse models of chronic pain
www.nature.com/articles/s41...
loading . . .
Single-dose psilocybin rapidly and sustainably relieves allodynia and anxiodepressive-like behaviors in mouse models of chronic pain - Nature Neuroscience
Hammo et al. show that a single dose of psilocybin rapidly and sustainably relieves both chronic pain and anxiodepressive-like behaviors in mice by restoring prefrontal activity through partial agonism at 5-HT2A and 5-HT1A receptors.
https://www.nature.com/articles/s41593-025-02068-0?utm_medium=email&_hsenc=p2ANqtz-9L5FwsKp1DvweL3UokqyL-MDcbo5sIxwbeWCNSnX85pgc2JRS3F8Sm4Gq--5wyUZ0QQypiezVdBcnAtnG3T7NmeRdtN5XtevrbrZXRHPOt5m9Nigc&_hsmi=119171277&utm_content=119171277&utm_source=hs_email
0
10
3
reposted by
Dose Response
Rich Haridy
7 months ago
Considering the phase 2 LSD for anxiety study has been published and is in the news a bit right now, here's a piece from last year where I spoke to the CMO of MindMed about the trial's somewhat unique protocol. Bit more detail here about how the dose sessions worked than in the actual study.
loading . . .
Some psychedelic medicine developers want to ditch the therapy aspect. What could go wrong?
Are drugs like psilocybin and MDMA still safe and effective in the absence of psychotherapy?
https://www.salon.com/2024/06/07/some-psychedelic-medicine-developers-want-to-ditch-the-therapy-aspect-what-could-go-wrong/
1
6
2
Neat- Spontaneous glutamate release activates mGluR signaling to drive rapid antidepressant responses
www.pnas.org/doi/10.1073/...
loading . . .
Spontaneous glutamate release activates mGluR signaling to drive rapid antidepressant responses | PNAS
Major depressive disorder affects millions worldwide, yet current treatments require prolonged administration. In contrast, ketamine produces rapid...
https://www.pnas.org/doi/10.1073/pnas.2510642122
7 months ago
0
0
0
reposted by
Dose Response
Chris Aiken, MD
8 months ago
Does
#ketamine
work via opioid system? This controversial idea finds new support in a randomized trial, where the opioid blocker naltrexone impeded ketamine's
#antidepressant
and glutamatergic effects:
www.ncbi.nlm.nih.gov/pubmed/40707...
#depression
#psychiatry
#pmhnp
1
6
1
reposted by
Dose Response
Matt Wall
7 months ago
add a skeleton here at some point
1
4
1
reposted by
Dose Response
Argel Aguilar Valles
8 months ago
www.nature.com/articles/s41...
loading . . .
Serotonin and psilocybin activate 5-HT1B receptors to suppress cortical signaling through the claustrum - Nature Communications
Our basic understanding of neuromodulation in the claustrum remains limited. Here Madden et al., identify a key mechanism by which serotonin and the psychedelic psilocybin modulate cortical signalling...
https://www.nature.com/articles/s41467-025-62980-8
0
4
3
reposted by
Dose Response
Katrin Preller
8 months ago
The emotional architecture of the psychedelic brain: If you are interested in
#psychedelics
and
#emotions
, take a look at our new paper:
authors.elsevier.com/sd/article/S...
. With Flora Moujaes,
@nathalierieser.bsky.social
, Lydia Belinger, Marcus Herdener, & Zarmeen Zahid. Just published in TICS.
loading . . .
ScienceDirect.com | Science, health and medical journals, full text articles and books.
https://authors.elsevier.com/sd/article/S1364-6613(25)00201-3
0
11
4
reposted by
Dose Response
Parker Singleton
8 months ago
🍄 Our new living systematic review and meta-analysis on psilocybin for depression is out. Here's what we found and the open science infrastructure we built to support it 🧪🧵
www.medrxiv.org/content/10.1...
1
36
27
you reached the end!!
feeds!
log in